[Journal of Hepatocellular Carcinoma] Although prognosis is poor for patients with hepatocellular carcinoma (HCC), especially those with cirrhosis, a prolonged subclinical growth period offers a window of time for curative treatment. In this review, researchers discuss the current status of screening, and what can be done to improve its potential.
[Breast Cancer: Targets and Therapy] A series of semi-structured interviews with breast specialists revealed how surgeons’ own beliefs regarding patients’ ability to accept death influenced how they managed treatment decision making.
[OncoTargets and Therapy] In this study, the efficacy of the chemotherapeutic regimen DCAG in patients aged 14 to 60 years with newly diagnosed AML was compared with standard therapy. Complete remission rate after the first cycle was comparable between the 2 regimens; but after the second cycle, a significant difference was observed.
[Journal of Hepatocellular Carcinoma]
[Cancer Management and Research] Despite the efficacy of radiotherapy, response to treatment can vary by breast cancer subtype and type of therapy. In this review, researchers summarize the prognostic differences and discuss potential reasons for them.
[Blood and Lymphatic Cancer: Targets and Therapy] This study analyzes the clinical outcomes reported with IDH1mut inhibitors and other agents in adult patients with IDH1mut R/R AML.
[Lung Cancer: Targets and Therapy] This research examines examine the clinical trial data that evaluated the combination of chemotherapy with immune checkpoint inhibitors for the front-line treatment of advanced NSCLC patients.
[Cancer Management and Research] The aim of this study was to establish a prognostic estimation of CHCs after resection (PECAR) score predicting recurrence on the basis of the clinicopathological data.
[Cancer Management and Research] In this report, researchers review evidence to date on the effectiveness of immune checkpoint inhibitors in combination for the treatment of non-small cell lung cancer.
[Cancer Management and Research] A meta-analysis of randomized controlled trials sought to confirm the effectiveness and safety of olaparib for the treatment of relapsed BRCA-mutated ovarian cancer.